Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

3.110 -0.120 (-3.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 23Andme Holding Co.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
ME Stock Alert: CEO Anne Wojcicki Enters $200 Million Buyout Offer for 23andMe
23andMe stock is up on Friday as investors react to an offer from the company's founder to take it private for 40 cents per share for ME. 
Via InvestorPlace
23andMe Special Committee responds to CEO’s take-private proposal
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces CEO’s Take-Private Proposal
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report Q1 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Looking Into 23andMe Holding's Recent Short Interest
Via Benzinga
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
Study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer 
From 23andMe, Inc.
Via GlobeNewswire
The 3 Best Personalized Nutrition Stocks to Buy Now
Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME
From Kahn Swick & Foti, LLC
Via Business Wire
3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts
Hercules Capital, Pfizer and Target offer stability, growth potential and reliable dividends in the realm of high-dividend stocks. 
Via InvestorPlace
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
From 23andMe, Inc.
Via GlobeNewswire
3 Ultra-High-Yield Dividend Stocks to Buy Hand Over Fist Right This Instant
Business development companies can be a lucrative source of passive income. 
Via The Motley Fool
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year. 
Via InvestorPlace
23andMe Launches New Genetic Report on Bipolar Disorder
Provides 23andMe+ Premium members with insight into their likelihood of developing the serious mental health illness based on thousands of genetic variants 
From 23andMe, Inc.
Via GlobeNewswire
Why 23andMe Stock Tumbled 10% on Tuesday
Is altruism a good idea for an unprofitable capitalistic enterprise? 
Via The Motley Fool
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
Study aims to fill research gap and empower people through access to information about their health 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
From 23andMe, Inc.
Via GlobeNewswire
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
Findings from 23andMe research on Parkinson’s disease published in Brain 
From 23andMe, Inc.
Via GlobeNewswire
ME Stock Earnings: 23andMe Holding Beats EPS, Beats Revenue for Q4 2024
ME stock results show that 23andMe Holding beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity 
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report Q4 and Full Year FY2024 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case
From Potter Handy LLP
Via Business Wire
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented 
From 23andMe, Inc.
Via GlobeNewswire
This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next
Matterport is being acquired by a real estate giant, but it might not be the last ex-SPAC to go this route. 
Via The Motley Fool
Nasdaq Down 0.5%; Lithium Americas Shares Slide
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future
Anne Wojcicki, CEO of 23andMe mulls taking the genetics company private amid market challenges. With declining revenue and a focus shift to drug development, the move seeks funding for potential... 
Via Benzinga
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.